Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Gynecology

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 72 articles:
HTML format



Single Articles


    March 2021
  1. QIN X, Zhou M, Lv H, Mao X, et al
    Corrigendum to "Long noncoding RNA LINC00657 inhibits cervical cancer development by sponging miR-20a-5p and targeting RUNX3" [Canc. Lett. 498 (2021) 130-141].
    Cancer Lett. 2021;508:73-75.
    PubMed    


  2. XANTHOULEA S, Konings GF, Saarinen N, Delvoux B, et al
    Pharmacological inhibition of 17beta-hydroxysteroid dehydrogenase impairs human endometrial cancer growth in an orthotopic xenograft mouse model.
    Cancer Lett. 2021 Mar 21. pii: S0304-3835(21)00124.
    PubMed     Abstract available


  3. WAN HY, Li QQ, Zhang Y, Tian W, et al
    Corrigendum to "MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells" [Cancer Letters 355 (2014) 148-158].
    Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00087.
    PubMed    


    February 2021
  4. KURNIT KC, Draisey A, Kazen RC, Chung C, et al
    Loss of CD73 shifts transforming growth factor-beta1 (TGF-beta1) from tumor suppressor to promoter in endometrial cancer.
    Cancer Lett. 2021 Feb 17. pii: S0304-3835(21)00062.
    PubMed     Abstract available


  5. LUO Q, Wu X, Zhang Y, Shu T, et al
    Corrigendum to 'ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2' [Canc. Lett. 427 (2018) 9-17].
    Cancer Lett. 2021;498:243.
    PubMed    


    January 2021
  6. LIU Y, Yang J, Shi Z, Tan X, et al
    In vivo selection of highly metastatic human ovarian cancer sublines reveals role for AMIGO2 in intra-peritoneal metastatic regulation.
    Cancer Lett. 2021 Jan 29. pii: S0304-3835(21)00048.
    PubMed     Abstract available


  7. BHARDWAJ V, Tan YQ, Wu MM, Ma L, et al
    Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
    Cancer Lett. 2021 Jan 8. pii: S0304-3835(21)00010.
    PubMed     Abstract available


    December 2020
  8. BUNGSY M, Palmer MCL, Jeusset LM, Neudorf NM, et al
    Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
    Cancer Lett. 2020 Dec 5. pii: S0304-3835(20)30649.
    PubMed     Abstract available


    November 2020
  9. MOSKOVICH D, Alfandari A, Finkelshtein Y, Weisz A, et al
    DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
    Cancer Lett. 2020 Nov 19. pii: S0304-3835(20)30603.
    PubMed     Abstract available


    October 2020
  10. QIN X, Zhou M, Lv H, Mao X, et al
    Long noncoding RNA LINC00657 inhibits cervical cancer development by sponging miR-20a-5p and targeting RUNX3.
    Cancer Lett. 2020 Oct 28. pii: S0304-3835(20)30578.
    PubMed     Abstract available


  11. YUAN Y, Cai X, Shen F, Ma F, et al
    HPV post-infection microenvironment and cervical cancer.
    Cancer Lett. 2020 Oct 26. pii: S0304-3835(20)30568.
    PubMed     Abstract available


  12. REVATHIDEVI S, Murugan AK, Nakaoka H, Inoue I, et al
    APOBEC: A molecular driver in cervical cancer pathogenesis.
    Cancer Lett. 2020 Oct 7. pii: S0304-3835(20)30503.
    PubMed     Abstract available


    September 2020
  13. KOK-TING WAN P, Ho-Yin Leung T, Kwan-Yee Siu M, Mo X, et al
    HPV-induced Nurr1 promotes cancer aggressiveness, self-renewal, and radioresistance via ERK and AKT signaling in cervical cancer.
    Cancer Lett. 2020 Sep 30. pii: S0304-3835(20)30495.
    PubMed     Abstract available


  14. XIE Z, Wang F, Lin L, Duan S, et al
    An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells.
    Cancer Lett. 2020 Sep 12. pii: S0304-3835(20)30467.
    PubMed     Abstract available


    August 2020
  15. TOCCI P, Cianfrocca R, Sestito R, Rosano L, et al
    Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer.
    Cancer Lett. 2020 Aug 26. pii: S0304-3835(20)30439.
    PubMed     Abstract available


  16. HU H, Chen Z, Ji L, Wang Y, et al
    ARID1A-dependent permissive chromatin accessibility licenses estrogen-receptor signaling to regulate circadian rhythms genes in endometrial cancer.
    Cancer Lett. 2020 Aug 25. pii: S0304-3835(20)30448.
    PubMed     Abstract available


  17. SUN Y, Yang X, Liu M, Tang H, et al
    Corrigendum to "B4GALT3 up-regulation by miR-27a contributes to the oncogenic activity in human cervical cancer cells." [Canc. Lett. 375 (2016) 284-292].
    Cancer Lett. 2020;493:16-18.
    PubMed    


    June 2020
  18. ZHANG M, Wang Y, Matyunina LV, Akbar A, et al
    The ability of miRNAs to induce mesenchymal-to-epithelial transition (MET) in cancer cells is highly dependent upon genetic background.
    Cancer Lett. 2020;480:15-23.
    PubMed     Abstract available


    March 2020
  19. XU Y, Li Y, Pan J, Kang X, et al
    EM2D9, a monoclonal antibody against Integrin a5b1, has potent antitumor activity on endometrial cancer in vitro and in vivo.
    Cancer Lett. 2020 Mar 3. pii: S0304-3835(20)30082.
    PubMed     Abstract available


    February 2020
  20. SHENG R, Li X, Wang Z, Wang X, et al
    Response to Comments on Circular RNAs and their Emerging Roles as Diagnostic and Prognostic Biomarkers in Ovarian Cancer.
    Cancer Lett. 2020 Feb 20. pii: S0304-3835(20)30068.
    PubMed    


  21. BERGSTEN TM, Burdette JE, Dean M
    Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.
    Cancer Lett. 2020 Feb 14. pii: S0304-3835(20)30080.
    PubMed     Abstract available


  22. GU C, Yang H, Chang K, Zhang B, et al
    Melatonin alleviates progression of uterine endometrial cancer by suppressing estrogen/ubiquitin C/SDHB-mediated succinate accumulation.
    Cancer Lett. 2020;476:34-47.
    PubMed     Abstract available


    January 2020
  23. YANG Y, Wei Q, Tang Y, Yuanyuan Wang, et al
    Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer.
    Cancer Lett. 2020 Jan 29. pii: S0304-3835(20)30043.
    PubMed     Abstract available


  24. WANG Y
    Comment on "Circular RNAs and their Emerging Roles as Diagnostic and Prognostic Biomarkers in Ovarian Cancer," Cancer Lett. 2020 Jan 2; 473 (2020) 139-147.
    Cancer Lett. 2020 Jan 29. pii: S0304-3835(20)30045.
    PubMed    


  25. NAN X, Wang J, Cheng H, Yin Z, et al
    Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
    Cancer Lett. 2020;469:195-206.
    PubMed     Abstract available


  26. SHENG R, Li X, Wang Z, Wang X, et al
    Circular RNAs and their Emerging Roles as Diagnostic and Prognostic Biomarkers in Ovarian Cancer.
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30665.
    PubMed     Abstract available


  27. ZHANG Y, Li X, Zhang J, Liang H, et al
    Natural killer T cell cytotoxic activity in cervical cancer is facilitated by the LINC00240/microRNA-124-3p/STAT3/MICA axis.
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30660.
    PubMed     Abstract available


    December 2019
  28. LIU W, Wang W, Wang X, Xu C, et al
    Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis.
    Cancer Lett. 2019;472:59-69.
    PubMed     Abstract available


  29. WANG R, Pan W, Jin L, Huang W, et al
    Human papillomavirus vaccine against cervical cancer: opportunity and challenge.
    Cancer Lett. 2019 Dec 5. pii: S0304-3835(19)30604.
    PubMed     Abstract available


  30. KASHYAP VK, Dan N, Chauhan N, Wang Q, et al
    VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway.
    Cancer Lett. 2019 Dec 3. pii: S0304-3835(19)30590.
    PubMed     Abstract available


    November 2019
  31. YANG Z, Jin P, Xu S, Zhang T, et al
    Corrigendum to "Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer" [Cancer Lett 415 (20-29)].
    Cancer Lett. 2019 Nov 15. pii: S0304-3835(19)30561.
    PubMed    


  32. WU H, Song S, Yan A, Guo X, et al
    RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1.
    Cancer Lett. 2019 Nov 6. pii: S0304-3835(19)30557.
    PubMed     Abstract available


    October 2019
  33. ALI R, Alabdullah M, Alblihy A, Miligy I, et al
    PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
    Cancer Lett. 2019 Oct 24. pii: S0304-3835(19)30538.
    PubMed     Abstract available


  34. GAO T, Zhang X, Zhao J, Zhou F, et al
    SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1alpha pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
    Cancer Lett. 2019 Oct 19. pii: S0304-3835(19)30526.
    PubMed     Abstract available


  35. ZHANG Z, Zhang L, Wang B, Wei R, et al
    MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.
    Cancer Lett. 2019 Oct 17. pii: S0304-3835(19)30518.
    PubMed     Abstract available


  36. ASANTE DB, Calapre L, Ziman M, Meniawy TM, et al
    Liquid biopsy in Ovarian cancer using Circulating Tumor DNA and Cells: Ready for Prime Time?
    Cancer Lett. 2019 Oct 11. pii: S0304-3835(19)30511.
    PubMed     Abstract available


    September 2019
  37. FENG S, Liu W, Bai X, Pan W, et al
    LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer.
    Cancer Lett. 2019;465:105-117.
    PubMed     Abstract available


    July 2019
  38. CAUMANNS JJ, van Wijngaarden A, Kol A, Meersma GJ, et al
    Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Cancer Lett. 2019 Jul 15. pii: S0304-3835(19)30400.
    PubMed     Abstract available


  39. PARAYATH NN, Gandham SK, Leslie F, Amiji MM, et al
    Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.
    Cancer Lett. 2019;461:1-9.
    PubMed     Abstract available


    June 2019
  40. CHEN J, Deng Y, Ao L, Song Y, et al
    The high-risk HPV oncogene E7 upregulates miR-182 expression through the TGF-beta/Smad pathway in cervical cancer.
    Cancer Lett. 2019 Jun 24. pii: S0304-3835(19)30376.
    PubMed     Abstract available


  41. ZHANG M, Jabbari N, Satpathy M, Matyunina LV, et al
    Sequence diverse miRNAs converge to induce mesenchymal-to-epithelial transition in ovarian cancer cells through direct and indirect regulatory controls.
    Cancer Lett. 2019 Jun 1. pii: S0304-3835(19)30340.
    PubMed     Abstract available


    May 2019
  42. KREUZINGER C, von der Decken I, Wolf A, Gamperl M, et al
    Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
    Cancer Lett. 2019;459:1-12.
    PubMed     Abstract available


  43. SU PH, Hsu YW, Huang RL, Chen LY, et al
    TET1 promotes 5hmC-dependent stemness, and inhibits a 5hmC-independent epithelial-mesenchymal transition, in cervical precancerous lesions.
    Cancer Lett. 2019;450:53-62.
    PubMed     Abstract available


  44. FOGG KC, Olson WR, Miller JN, Khan A, et al
    Alternatively activated macrophage-derived secretome stimulates ovarian cancer spheroid spreading through a JAK2/STAT3 pathway.
    Cancer Lett. 2019 May 23. pii: S0304-3835(19)30324.
    PubMed     Abstract available


    March 2019
  45. HAN W, Zhang Y, Niu C, Guo J, et al
    BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.
    Cancer Lett. 2019;445:45-56.
    PubMed     Abstract available


  46. CHE Y, Li Y, Zheng F, Zou K, et al
    TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling.
    Cancer Lett. 2019;452:1-13.
    PubMed     Abstract available


    February 2019
  47. VLIET-GREGG PA, Robinson KL, Levan J, Matsumoto LR, et al
    NFX1-123 is highly expressed in cervical cancer and increases growth and telomerase activity in HPV 16E6 expressing cells.
    Cancer Lett. 2019 Feb 15. pii: S0304-3835(19)30102.
    PubMed     Abstract available


  48. ZHAO H, Jin L, Li Y, Zhang C, et al
    Oncofertility: What can we do from bench to bedside?
    Cancer Lett. 2019;442:148-160.
    PubMed     Abstract available


    November 2018
  49. RADHAKRISHNAN R, Ha JH, Jayaraman M, Liu J, et al
    Ovarian Cancer Cell-derived Lysophosphatidic Acid Induces Glycolytic Shift and Cancer-associated Fibroblast-Phenotype in Normal and Peritumoral Fibroblasts.
    Cancer Lett. 2018 Nov 29. pii: S0304-3835(18)30689.
    PubMed     Abstract available


    October 2018
  50. LV Q, Xie L, Cheng Y, Shi Y, et al
    A20-mediated deubiquitination of ERalpha in the microenvironment of CD163(+) macrophages sensitizes endometrial cancer cells to estrogen.
    Cancer Lett. 2018;442:137-147.
    PubMed     Abstract available


  51. PENG Y, Kajiyama H, Yuan H, Nakamura K, et al
    PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.
    Cancer Lett. 2018;442:181-192.
    PubMed     Abstract available


    September 2018
  52. YANG P, Su C, Luo X, Zeng H, et al
    Dietary oleic acid-induced CD36 promotes cervical cancer cell growth and metastasis via up-regulation Src/ERK pathway.
    Cancer Lett. 2018 Sep 10. pii: S0304-3835(18)30559.
    PubMed     Abstract available


    August 2018
  53. YANG Z, Jin P, Xu S, Zhang T, et al
    Corrigendum to "Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer" [Cancer Lett. 2018 Feb 28; 415:20-29].
    Cancer Lett. 2018 Aug 18. pii: S0304-3835(18)30502.
    PubMed    


  54. KREITZBURG KM, Fehling SC, Landen CN, Gamblin TL, et al
    FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
    Cancer Lett. 2018 Aug 15. pii: S0304-3835(18)30527.
    PubMed     Abstract available


  55. CHEN X, Zhou J, Li X, Wang X, et al
    Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype.
    Cancer Lett. 2018;435:80-91.
    PubMed     Abstract available


    July 2018
  56. KARTHIKEYAN S, Russo A, Dean M, Lantvit DD, et al
    Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model.
    Cancer Lett. 2018;433:221-231.
    PubMed     Abstract available


    June 2018
  57. MALDONADO L, Brait M, Izumchenko E, Begum S, et al
    Integrated Transcriptomic and Epigenomic Analysis of Ovarian Cancer Reveals Epigenetically Silenced GULP1.
    Cancer Lett. 2018 Jun 28. pii: S0304-3835(18)30436.
    PubMed     Abstract available


  58. ZHANG Q, Li Y, Miao C, Wang Y, et al
    Anti-angiogenesis effect of Neferine via regulating autophagy and polarization of tumor-associated macrophages in high-grade serous ovarian carcinoma.
    Cancer Lett. 2018 Jun 4. pii: S0304-3835(18)30390.
    PubMed     Abstract available


    April 2018
  59. MENG Y, Chen CW, Yung MMH, Sun W, et al
    DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
    Cancer Lett. 2018 Apr 25. pii: S0304-3835(18)30296.
    PubMed     Abstract available


  60. LUO Q, Wu X, Zhang Y, Shu T, et al
    ARID1A ablation leads to Multiple Drug Resistance in ovarian cancer via transcriptional activation of MRP2.
    Cancer Lett. 2018 Apr 13. pii: S0304-3835(18)30274.
    PubMed     Abstract available


    March 2018
  61. VAN HEETVELDE M, Van Bockstal M, Poppe B, Lambein K, et al
    Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
    Cancer Lett. 2018 Mar 23. pii: S0304-3835(18)30223.
    PubMed     Abstract available


  62. VIRANI NA, Thavathiru E, McKernan P, Moore K, et al
    Anti-CD73 and Anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
    Cancer Lett. 2018 Mar 21. pii: S0304-3835(18)30224.
    PubMed     Abstract available


    February 2018
  63. HASSAN W, Chitcholtan K, Sykes P, Garrill A, et al
    Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells.
    Cancer Lett. 2018 Feb 9. pii: S0304-3835(18)30140.
    PubMed     Abstract available


  64. RICCIARDELLI C, Lokman NA, Sabit I, Gunasegaran K, et al
    Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.
    Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30131.
    PubMed     Abstract available


    January 2018
  65. GUO J, Yang Z, Yang X, Li T, et al
    miR-346 functions as a pro-survival factor under ER stress by activating mitophagy.
    Cancer Lett. 2018;413:69-81.
    PubMed     Abstract available


    December 2017
  66. YANG Z, Jin P, Xu S, Zhang T, et al
    Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer.
    Cancer Lett. 2017;415:20-29.
    PubMed     Abstract available


    November 2017
  67. TOMAR S, Plotnik JP, Haley J, Scantland J, et al
    ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.
    Cancer Lett. 2017;414:190-204.
    PubMed     Abstract available


    October 2017
  68. YANG X, Wang CC, Lee WYW, Trovik J, et al
    Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.
    Cancer Lett. 2017 Oct 26. pii: S0304-3835(17)30665.
    PubMed     Abstract available


  69. WANG J, Man GCW, Chan TH, Kwong J, et al
    A prodrug of green tea polyphenol (-)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer.
    Cancer Lett. 2017 Oct 9. pii: S0304-3835(17)30623.
    PubMed     Abstract available


  70. PISTOLLATO F, Calderon Iglesias R, Ruiz R, Aparicio S, et al
    The use of natural compounds for the targeting and chemoprevention of ovarian cancer.
    Cancer Lett. 2017 Oct 7. pii: S0304-3835(17)30619.
    PubMed     Abstract available


  71. SHU T, Li Y, Wu X, Li B, et al
    Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Cancer Lett. 2017 Oct 6. pii: S0304-3835(17)30609.
    PubMed     Abstract available


    September 2017
  72. LOUGHRAN EA, Phan RC, Leonard AK, Tarwater L, et al
    Multiparity Activates Interferon Pathways in Peritoneal Adipose Tissue and Decreases Susceptibility to Ovarian Cancer Metastasis in a Murine Allograft Model.
    Cancer Lett. 2017 Sep 27. pii: S0304-3835(17)30581.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: